CLINICAL_TRIALS
trial_result
· 2014-03-31
Clinical Trial Update: Safety of PCI-32765 in Chronic Lymphocytic Leukemia [Phase 1, Phase 2]
Summary
Clinical trial update reporting safety data for the BTK inhibitor ibrutinib (PCI-32765) in patients with chronic lymphocytic leukemia and small lymphocytic lymp…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pharmacyclics LLC. | Conditions: B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-03-31